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Summary To monitor mortality rates from malignant melanoma we analysed all patients in Sweden (6,324)
who died of malignant melanoma in 1953 through 1987. Age-standardised rates per 105 increased from 1.1 to
4.0 in men and from 1.0 to 2.6 in women. The average annual increase levelled off in men from 4.6% during
1953-1967 to 2.0% in 1978-1987; and in women from 3.7% to 0%. Multivariate analyses showed that the
change in rates for men was mainly due to a birth-cohort effect, whereas in women the rates changed similarly
in all age-groups in accordance with a time-period effect. The risk of dying of malignant melanoma increased
in men for birth cohorts up to 1932, whereas in women the rise continued for cohorts born as late as 1947.
The best-fitted multivariate models were extrapolated to the year 2007, among men a slight increase in
mortality rates seemed likely, whereas among women the rates will probably remain unchanged.
The incidence of malignant melanoma has been increasing in
white populations throughout the world during the last few
decades (Jensen & Bolander, 1980; Hakulinen et al., 1986).
No apparent change in diagnostic criteria can explain this
increase (van der Esch et al., 1991). In many countries,
malignant melanoma may become one of the commonest
malignant tumours and it therefore constitutes a growing
problem in cancer control. However, studies of trends in
survival show that the prognosis of the disease has improved
(Shaw et al., 1977; Balch et al., 1983; Thorn et al., 1989). In
Sweden the relative risk of dying of malignant melanoma
within 5 years after diagnosis decreased by 68% in men and
71% in women from 1960-1964 to 1980-1982 (Thorn et al.,
1989). This improvement was larger than for any other solid
tumour in Sweden (Adami et al., 1989). Probably the increase
in public awareness of malignant melanoma has entailed
earlier diagnosis and thus facilitated curative treatment. This
explanation of the temporal trends in survival is also sup-
ported by an increasing proportion of smaller and thinner
tumours in recent surveys of histopathological data (Shafir et
al., 1982; English et al., 1986; Drzewiecki et al., 1990).
Notwithstanding these improvements there is still steady
rise in the death rates from malignant melanoma in many
countries (Jensen & Bolander, 1980; Lee et al., 1979; Lee,
1985). The only exception is Queensland, Australia, where a
stabilisation of mortality rates was apparent in males after
1960-1964 and in females after 1965-1969 (Holman et al.,
1980).
The present study was based on mortality rates from
malignant melanoma in Sweden from 1953 to 1987. In addi-
tion to calcuations of age-standardised and age-specific rates,
multivariate analysis was done to separate the effects of time
period from those of birth cohort to further explain the
trends. The resulting multivariate models were also ex-
trapolated to estimate the mortality rates until the year
2007.
Subjects and methods
Deathsfrom malignant melanoma
The Swedish National Cause of Death Register
systematically collects information on dates and causes of
deaths based on all Swedish citizens who have died during a
given calendar year, including those who have died outside
the country (Statistics Sweden, 1954-1989). The cause of
death is registered in accordance with the International
Classification of Diseases (World Health Organization, 1967).
The underlying cause of death and the contributory cause of
death - if a malignant disease - were registered in the Cause
of Death Register up to 1980. After that year only a single
underlying cause of death was registered. A total of 6,324
deaths from malignant melanoma was registered in the Cause
of Death Register from 1953 through 1987. These cases were
distributed by sex, age and 5-year periods as shown in Table
I.
Statistical methods
Age-standardised mortality rates were calculated for men and
women annually. The direct method of standardisation
(Fleiss, 1981) was used with the Swedish population of 1970
as reference. A log-linear regression model, which implies a
constant annual percentage change, was used to estimate the
temporal trends of the rates. Age-specific mortality rates were
estimated as the average rate per year during each 5-year
time period, starting with 1953-1957 and ending with
1983-1987, using the age-groups <30, 30-39, 40-49,
50-59, 60-69 and > 70 years of age.
In the multivariate analysis the number of deaths was
assumed to be Poisson-distributed, with a mean which
depends on multiplication of the explanatory variables of
age, period and cohort. The full model may be formulated
as
Lijk= Nijk exp (@ij7k),
where N is person-years and mi, Pj and ?k are the effects of
age, period and cohort. The model was estimated by the
maximum likelihood method, using the GLIM software
package (Baker & Nelder, 1978). Submodels, such as a com-
bination of age and period and a combination of age and
cohort, were fitted in addition to the full model. The special
case when the effects of period or cohort on the logarithmic
rates in age-period and age-cohort models was assumed to be
linear was also considered. In that case, it was impossible to
separate the period effects from the cohort effects, and the
combined linear effect is denoted 'drift' (Clayton & Schifflers,
1987). The model fit was evaluated in terms of the deviance,
which has an asymptotic chi-square distribution. By deter-
mining the difference in deviance, various models can be
compared. When the deviance is close to the degrees of
freedom of the model, the fit may be considered ade-
quate.
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Table I Number of deaths and age-standardised mortality rates in
patients with malignant melanoma in Sweden, 1953-1987, by sex and year
of death
Number of deaths Age-standardised ratesa
Year Men Women Men Women
1953-1957 213 167 1.31 1.00
1958-1962 327 242 1.90 1.31
1963- 1967 373 299 2.05 1.52
1968-1972 536 397 2.82 1.89
1973-1977 615 435 3.13 1.92
1978- 1982 713 573 3.54 2.41
1983- 1987 843 591 4.07 2.39
Total 3620 2704
aAverage rate per year.
For the analysis, 13 five-year age-groups (ranging from
ages 20-24 to 80-84 years) and 7 five-year calendar periods
from 1953 to 1987 were defined. In all 19 ten-year overlap-
ping birth cohorts were used, starting at 1868-1877 and
ending at 1958-1967. The risk associated with a certain
age-group (or period or cohort) relative to a chosen reference
group was obtained by exponentiation of the parameter (for
example, exp (i).
Forecasts based on the multivariate models were produced
for four 5-year periods in the future. The estimates of the
unknown period effects and cohort effects were obtained by
linear regressions based on arbitrarily chosen numbers of the
most recent period and cohort values. These analyses were
done on the logarithms of the sets of values, the form in
which the underlying model is linear (Osmond, 1985).
Results
Age-standardised rates
The age-standardised mortality rates increased from 1.1 per
105 in 1953 to 4.0 in 1987 in men and from 1.0 to 2.6,
respectively, in women. The average annual percentage
change during the entire study period was 3.7% (95%
confidence interval (CI) = 3.2-4.2%) in men and 2.8% (95%
CI = 2.4-3.2%) in women. When the trends were estimated
for the 15-year period 1953-1967, the corresponding annual
increase in men was 4.7% (95% CI = 2.5-6.8%) and in
women 3.7% (95% CI = 2.3-5.1%). However, during the
following 10-year period, 1968-1977, the annual change
decreased in men to 2.4% (95% CI = 1.5-3.4%) and in
women to 0.2% (95% CI =-1.5-1.8%). Similarly, during the
last 10-year period, 1978-1987, the annual changes in rates
were in men 2.0% (95% CI = 0-4.2%) and in women 0%
(95% CI= - 1.9-1.8%). Thus, in men the rate of increase
levelled off during later years and in women the mortality
rates stabilised. However, the rates in women stabilised at a
higher level during 1978-1987 than 1968-1977 (Figure 1).
Age-specific rates
In men younger than 50 years of age, there was no increase
in the mortality rates after 1968. In contrast, men aged 50
years or more showed increasing rates during the entire study
period (Figure 2).
In women aged 30 to 50 years, the rates increased slightly,
except during the last five-year time period, 1983-1987.
Women older than 50 years had steadily increasing mortality
rates, except those older than 70 years who had decreasing
rates during the last 5-year time period (Figure 3).
Multivariate analysis
In both sexes, 'drift'-models (which includes linear effects of
period and cohort) were significantly superior to simple age
models in explaining the mortality rates. Further, in men, an
age-cohort model - which in contrast to the age-drift model
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Figure 1 Age-standardised (to the Swedish population in 1970)
mortality rates of malignant melanoma in men and women,
Sweden, 1953-1987.
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Figure 2 Age-specific mortality rates of malignant melanoma in
men, Sweden, 1953-1987.
allows the cohort effects to be non-linear - was a significant
improvement (P<0.01) on the age-drift model. An age-
period model was also an improvement on the age-drift
model (P<0.05). The full model (age + period + cohort) fur-
ther lowered the deviance, however, the change was not
significant (P = 0.07) compared to the age-cohort model. In
women, the use of an age-cohort model did not significantly
improve the age-drift model. An age-period model, however,
was a significant improvement (P<0.01) on the age-drift
model. The full model was not an improvement on the
age-period model (P = 0.29) (Table II).
In the age-cohort model in men, the relative risk of dying
of malignant melanoma increased continuously by birth
cohort up to a seven-fold higher relative risk in those bornMORTALITY FROM MALIGNANT MELANOMA 565
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Figure 3 Age-specific mortality rates of malignant melanoma in
women, Sweden, 1953-1987.
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Figure 4 Relative risk of dying of malignant melanoma in suc-
cessive birth cohorts of men and women, Sweden, 1953-1987.
Reference birth cohort 1868-1877 (relative risk = 1).
Table II Goodness-of-fit tests for different age-, period- and
cohort-specific models of mortality in malignant melanoma in men
and women, Sweden, 1953-1987a
Deviance
Model d.f. Men Women
Mean only 90 2696 1706
Age 78 520.7 285.1
Age + drift 77 167.9 106.2
Age + cohort 60 79.88b 84.27
Age + period 72 155.1c 87.28b
Age + cohort + period 55 69.71b 67.56c
aModels expressed by the deviance and degrees of freedom. bSignifi-
cant at the I% level vs age + drift. cSignificant at the 5% level vs
age + drift.
around 1932, compared to men born in 1878-1887; in later-
born cohorts the risk decreased gradually and markedly to a
relative risk below four in the youngest cohort (Figure 4). In
women, however, the relative risk by cohort increased almost
sevenfold up to the birth cohort 1943-1952 before declining
(Figure 4). The age-effects in the age-cohort model had a
nearly constant slope for both men and women.
The relative risk by period increased continuously through-
out the study period for men up to 3.0 compared to the
earliest time period 1953-1957. In women the risk increased
stepwise up to 2.6 and did not change during the time period
1973-1977 as compared to 1968-1972 and during
1983-1987 as compared to 1978-1982 (Figure 5).
Extrapolations offuture mortality rates
In men, the age-period model generated considerably higher
estimates than the age-cohort model. In both models the
predictions were rather insensitive to using two or five recent
period values or cohort values as the basis for the extrapola-
tion (Table III). Since the mortality trends in men have
mostly followed a cohort pattern hitherto, this model was
considered more reliable even for future predictions. Thus, an
about 35% increase in age-standardised mortality rates was
estimated for the 20-year period following 1987. However,
the rate of increase will probably decline gradually from
about 14% between the first two 5-year periods to less than
5% between the last two periods.
In women, predictions from the cohort model were iden-
tical when two and five recent cohort values were included.
In contrast, the extrapolation of period effects which, accord-
ing to the multivariate analysis may be more relevant in
women, was very sensitive to the number of period values
included. Estimates based on two period values (10 years of
the observation) suggest that the maximum was reached in
1978 through 1987 and that future age-standardised rates will
stabilise at annual rates close to 3 per 105. Predictions that
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Figure 5 Relative risk of dying of malignant melanoma in suc-
cessive time periods in men and women, Sweden, 1953-1987.
Reference time period, 1953-1957 (relative risk = 1).
proceed from five recent period values, on the other hand,
are strongly influenced by the apparent stepwise increase in
mortality rate from 1973-1977 to 1978-1982 (Figure 5).
Consequently, this model predicts a continuing 80% increase
from 1987 through the year 2007 (Table III).
Discussion
Our analysis of mortality rates from malignant melanoma in
Sweden 1953-1987 showed increasing rates in men and
stabilising rates in women. The change in rates was best
explained by cohort effects in men and by period effects in
women. The relative risk of dying of malignant melanoma
increased in men by birth cohort continuously up to men
born around 1932, whereas in women the rise continued for
cohorts born as late as 1947. In future, the increase in
mortality rates will probably slow down for men, whereas in
women predictions are more uncertain due to a stepwise
increase in the late 1970s. Thus, mortality rates in women
may stabilise around 3 per I05 or increase up to 5.7 per I05
during the next 20 years.
Mortality rates from malignant melanoma are affected by
both the causative factors determining the incident number
of cases and by factors related to the prognosis of the
disease. One possible source of error affecting trends in mor-
tality is the varying accuracy of the certified underlying cause
of death. In Sweden, a comparison between diagnoses of skin
cancer and malignant melanoma in the Stockholm Cancer
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Table HI Age-standardised mortality rates from malignant melanoma in patients between 20-84 years
of age during 5-year periods, in Sweden, 1953-1987, and extrapolations of future mortality rates. The
extrapolated rates are based on the two most recent period- or cohort-values and on five values,
respectively
Observed age-standardised ratesa
Period Men Women
1953-1957 1.77 1.20
1958-1962 2.50 1.78
1963-1967 2.76 2.01
1968-1972 3.78 2.52
1973-1977 4.16 2.52
1978-1982 4.71 3.18
1983-1987 5.47 3.17
Extrapolated age-standardised ratesa
Men Women
age-period model age-cohort model age-period model age-cohort model
2 values 5 values 2 values 5 values 2 values 5 values 2 values 5 values
1988-1992 6.26 6.46 6.26 6.26 3.12 3.85 3.79 3.79
1993-1997 7.24 7.53 6.85 6.87 3.09 4.40 4.24 4.24
1998-2002 8.37 8.78 7.21 7.25 3.06 5.01 4.65 4.65
2003-2007 9.68 10.25 7.42 7.50 3.04 5.72 4.99 4.99
aAverage rate per 105 per year.
Register and the certified underlying cause of death in the
Cause of Death Register, during 1978, showed concordant
diagnoses in 88% of the cases (Mattsson et al., 1984). To our
knowledge, no such investigation has been performed for the
years after 1978 or specifically for malignant melanoma.
However, the reporting practices have probably improved
and we consider it unlikely that the results of our study are
seriously biased because of changes in reporting practices.
Mortality rates from malignant melanoma in Sweden,
adjusted to the European standard population for com-
parison (IARC, 1976), were lower than rates in Australia and
New Zealand; they were similar to those in the United States
and higher than the rates recorded in Canada, England and
Wales (Lee et al., 1979; Venzon & Moolgavkar, 1984). In
men, the mean annual percentage increases in mortality rates,
from the 1950s to the 1970s, were almost identical in Sweden,
Australia and New Zealand, whereas they were lower among
men in England and Wales, Canada and the white popula-
tion of the United States. Among women the increases in
mortality rates were similar in Sweden, New Zealand, Aust-
ralia, Canada, England and Wales but lower among white
women in the United States.
Age-period-cohort models are superior to simple descrip-
tive methods. It is possible to test whether a significant
improvement is obtained when further factors are included in
the model. It can be stated whether the full model is an
improvement on an age-period or an age-cohort model.
However, the individual parameters of the full model cannot
be identified, this fact makes the interpretation of the results
rather difficult and limits the use of the method. In our
analysis, two-factor models (age-cohort or age-period) were
found to be adequate and it was not necessary to identify the
full model.
In contrast to earlier studies, in which it was mainly cohort
effects that explained the changes in mortality rates in both
sexes (Lee et al., 1979; Holman et al., 1980; Venzon &
Moolgavkar, 1984), we found that period effects were more
important in women. Similar results were obtained in a
multivariate analysis of incidence rates of malignant
melanoma in Sweden (Thorn et al., 1990). Thus the temporal
changes in exposure to causative factors - as revealed by
trends in incidence - are fairly well reflected also by the
mortality rates. However, the increasing incidence trend has
been more pronounced than the mortality trend particularly
in women. This discrepancy can be explained by the large
temporal improvement in relative survival from malignant
melanoma documented earlier (Thorn et al., 1989).
In the forecasts, the number of values chosen as the basis
for the extrapolations is crucial for the results predicted with
the age-period model. The age-cohort model is less sensitive
to the number of values included because the mortality is
small in the youngest age-groups which are influenced by the
extrapolated cohort-values. Consequently, the two alternative
extrapolations in our study gave largely similar mortality
rates in the cohort model, whereas in the period model the
results were different, especially for women (Table III).
The overall achievements in control of malignant
melanoma are best evaluated by studying the changes in the
mortality rates. The planning of interventional strategies -
e.g., educational programs to reduce sun exposure and
screening programs for earlier diagnosis - should be guided
by estimates of the mortality rates in the future. Malignant
melanoma currently accounts for about 1.5% of all cancer
related deaths in Sweden (Statistics Sweden, 1990). Our study
suggests that the mortality from malignant melanoma is
likely to increase only slightly during the next 20 years.
Under such circumstances, malignant melanoma will retain a
limited quantitative role in the overall burden of death from
cancer.
This study was supported by grants from the Swedish Cancer
Society.
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